The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp.

Filho, Pedro Antônio Nogueira; Hazarbassanov, Rossen Mihaylov; Grisolia, Ana Beatriz Diniz; Pazos, Henrique Baltar; Kaiserman, Igor; Gomes, José Álvaro Pereira

doi:10.1136/bjo.2010.201194

Cited by 59 publications

(37 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Though McCulley 1982 previously classified chronic blepharitis into six categories, it more recently has been divided into three categories: staphylococcal, seborrheic, and meibomian gland dysfunction (MGD) (AAO 2008). Further, many clinicians prefer to classify blepharitis based on anatomic location where anterior blepharitis causes inflammation primarily at the base of the eyelashes (staphylococcal and seborrheic blepharitis are often grouped together and referred to as anterior blepharitis), posterior blepharitis affects the posterior lid margin (the section of the eyelid that comes into contact with the cornea and bulbar conjunctiva), and marginal blepharitis includes both anterior and posterior blepharitis (Nelson 2011). MGD affects primarily the oil glands located on the posterior lid and therefore it is included as a subset of posterior blepharitis.…”

Section: Introductionmentioning

confidence: 99%

“…Posterior blepharitis is characterized by inflammation of the posterior lid margin and has various causes, such as MGD, infectious or allergic conjunctivitis, and systemic conditions such as acne rosacea (Nelson 2011). MGD is a condition that affects the glands on the posterior lid margin that are responsible for secreting meibum, the outermost oily layer of the tear film.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interventions for chronic blepharitis

Lindsley

Matsumura

Hatef

et al. 2012

Cochrane Database of Systematic Reviews

120

113

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Interventions for chronic blepharitis

Lindsley

Matsumura

Hatef

et al. 2012

Cochrane Database of Systematic Reviews

120

113

View full text Add to dashboard Cite

show abstract

“…[54][55]. Filho et al [56] examined the effectiveness of oral ivermectin in patients with blepharitis with proven Demodex spp. infestation.…”

Section: Diagnosismentioning

confidence: 99%

Blepharitis and Demodex spp. infection

et al. 2017

View full text Add to dashboard Cite

According to the latest reports Demodex mites appear to play an important role in the pathogenesis of chronic blepharitis. Demodex mites are cosmopolitan and are present in many species of mammals. In this paper we describe two species that are found in humans: Demodex folliculorum and D. brevis. Infection occurs during direct contact with an affected person and also through contact with dust containing eggs of the parasite, through contact with bed linen, as well as cosmetics used together with an affected person. Treatment of chronic blepharitis caused by D. folliculorum and D. brevis is difficult and time consuming. Some improvement can be achieved after topical application of yellow mercury ointment, sulphuric ointment, camphor oil, crotamiton, cholinesterase inhibitors, sulfacetamide, steroids, antibiotics and antifungal drugs. Good results have been achieved with oral ivermectin and permethrin cream. However, the best results were observed after treatment with metronidazole.

show abstract

“…[38][39][40] Selective binding of ivermectin to glutamate-gated chloride channels in invertebrates has been shown to reduce Demodex colonization in both demodicidosis and blepharitis. Ivermectin induces anti-inflammatory effects via nuclear factor-κB pathway inhibition and subsequently decreases the release of inflammatory cytokines.…”

mentioning

confidence: 99%

Update on the Management of Rosacea

Weinkle

Doktor

Emer

2015

Plastic Surgical Nursing

View full text Add to dashboard Cite

Abstract:Refining diagnostic criteria has identified key characteristics differentiating rosacea, a chronic skin disorder, from other common cutaneous inflammatory conditions. The current classification system developed by the National Rosacea Society Expert Committee consists of erythematotelangiectatic, papulopustular, phymatous, and ocular subtypes. Each subtype stands as a unique entity among a spectrum, with characteristic symptoms and physical findings, along with an intricate pathophysiology. The main treatment modalities for rosacea include topical, systemic, laser, and light therapies. Topical brimonidine tartrate gel and calcineurin inhibitors are at the forefront of topical therapies, alone or in combination with traditional therapies such as topical metronidazole or azelaic acid and oral tetracyclines or isotretinoin. Vascular laser and intense pulsed light therapies are beneficial for the erythema and telangiectasia, as well as the symptoms (itching, burning, pain, stinging, swelling) of rosacea. Injectable botulinum toxin, topical ivermectin, and microsecond long-pulsed neodymium-yttrium aluminum garnet laser are emerging therapies that may prove to be extremely beneficial in the future. Once a debilitating disorder, rosacea has become a well known and manageable entity in the setting of numerous emerging therapeutic options. Herein, we describe the treatments currently available and give our opinions regarding emerging and combination therapies.

show abstract

The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp.

Cited by 59 publications

References 6 publications

Interventions for chronic blepharitis

Interventions for chronic blepharitis

Blepharitis and Demodex spp. infection

Update on the Management of Rosacea

Contact Info

Product

Resources

About